High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma with or without antiretroviral therapy during antineoplastic agents.
Gastaldi
R
R
Martino
P
P
Gentile
G
G
De Propris
M S
MS
Pirillo
M F
MF
De Vellis
A
A
Mandelli
F
F
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D018655:Lymphocyte Count; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D014750:Vincristine / Q000008:administration & dosage
D000998:Antiviral Agents; D014750:Vincristine; D003907:Dexamethasone; D003520:Cyclophosphamide; D015255:Idarubicin